These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21057220)

  • 1. Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer.
    Tanaka Y; Terai Y; Tanabe A; Sasaki H; Sekijima T; Fujiwara S; Yamashita Y; Kanemura M; Ueda M; Sugita M; Franklin WA; Ohmichi M
    Cancer Biol Ther; 2011 Jan; 11(1):50-7. PubMed ID: 21057220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer.
    de Graeff P; Crijns AP; Ten Hoor KA; Klip HG; Hollema H; Oien K; Bartlett JM; Wisman GB; de Bock GH; de Vries EG; de Jong S; van der Zee AG
    Br J Cancer; 2008 Jul; 99(2):341-9. PubMed ID: 18628764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations.
    Lazzara MJ; Lane K; Chan R; Jasper PJ; Yaffe MB; Sorger PK; Jacks T; Neel BG; Lauffenburger DA
    Cancer Res; 2010 May; 70(9):3843-50. PubMed ID: 20406974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations.
    Hiramatsu M; Ninomiya H; Inamura K; Nomura K; Takeuchi K; Satoh Y; Okumura S; Nakagawa K; Yamori T; Matsuura M; Morikawa T; Ishikawa Y
    Lung Cancer; 2010 Oct; 70(1):94-102. PubMed ID: 20117855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.
    Posadas EM; Liel MS; Kwitkowski V; Minasian L; Godwin AK; Hussain MM; Espina V; Wood BJ; Steinberg SM; Kohn EC
    Cancer; 2007 Apr; 109(7):1323-30. PubMed ID: 17330838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
    Han SW; Kim TY; Jeon YK; Hwang PG; Im SA; Lee KH; Kim JH; Kim DW; Heo DS; Kim NK; Chung DH; Bang YJ
    Clin Cancer Res; 2006 Apr; 12(8):2538-44. PubMed ID: 16638863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between EGFR gene mutation pattern and Akt phosphorylation in pulmonary adenocarcinomas.
    Ikeda S; Takabe K; Inagaki M; Funakoshi N; Suzuki K; Shibata T
    Pathol Int; 2007 May; 57(5):268-75. PubMed ID: 17493174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
    Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
    Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of pERK and pAKT in pediatric high grade astrocytomas: correlation with YKL40 and prognostic significance.
    Antonelli M; Massimino M; Morra I; Garrè ML; Gardiman MP; Buttarelli FR; Arcella A; Giangaspero F
    Neuropathology; 2012 Apr; 32(2):133-8. PubMed ID: 21978279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of epidermal growth factor receptor and mitogen-activated protein kinase with cystic neoplasms of the pancreas.
    Kuboki Y; Shiratori K; Hatori T; Fujita I; Kimijima A; Yamamoto M; Kobayashi M; Furukawa T
    Mod Pathol; 2010 Aug; 23(8):1127-35. PubMed ID: 20495538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
    Castellvi J; Garcia A; Rojo F; Ruiz-Marcellan C; Gil A; Baselga J; Ramon y Cajal S
    Cancer; 2006 Oct; 107(8):1801-11. PubMed ID: 16983702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer.
    Hosokawa S; Toyooka S; Fujiwara Y; Tokumo M; Soh J; Takigawa N; Hotta K; Yoshino T; Date H; Tanimoto M; Kiura K
    Lung Cancer; 2009 Oct; 66(1):107-13. PubMed ID: 19185949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
    Cappuzzo F; Hirsch FR; Rossi E; Bartolini S; Ceresoli GL; Bemis L; Haney J; Witta S; Danenberg K; Domenichini I; Ludovini V; Magrini E; Gregorc V; Doglioni C; Sidoni A; Tonato M; Franklin WA; Crino L; Bunn PA; Varella-Garcia M
    J Natl Cancer Inst; 2005 May; 97(9):643-55. PubMed ID: 15870435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling.
    Zimmer S; Kahl P; Buhl TM; Steiner S; Wardelmann E; Merkelbach-Bruse S; Buettner R; Heukamp LC
    J Cancer Res Clin Oncol; 2009 May; 135(5):723-30. PubMed ID: 19002495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
    Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
    Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells.
    Ohta T; Ohmichi M; Shibuya T; Takahashi T; Tsutsumi S; Takahashi K; Kurachi H
    Cancer Biol Ther; 2012 Apr; 13(6):408-16. PubMed ID: 22313686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity.
    Wang H; Zhou M; Shi B; Zhang Q; Jiang H; Sun Y; Liu J; Zhou K; Yao M; Gu J; Yang S; Mao Y; Li Z
    Neoplasia; 2011 May; 13(5):461-71. PubMed ID: 21532887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.
    Watanabe S; Hayashi H; Haratani K; Shimizu S; Tanizaki J; Sakai K; Kawakami H; Yonesaka K; Tsurutani J; Togashi Y; Nishio K; Ito A; Nakagawa K
    Cancer Sci; 2019 Jan; 110(1):52-60. PubMed ID: 30390416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
    Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
    Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC).
    Mukohara T; Kudoh S; Yamauchi S; Kimura T; Yoshimura N; Kanazawa H; Hirata K; Wanibuchi H; Fukushima S; Inoue K; Yoshikawa J
    Lung Cancer; 2003 Aug; 41(2):123-30. PubMed ID: 12871775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.